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promotes actin polymerization to aid
endocytic vesicle maturation.
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Multiple proteins act co-operatively in mammalian
clathrin-mediated endocytosis (CME) to generate en-
docytic vesicles from the plasma membrane. The
principles controlling the activation and organization
of the actin cytoskeleton during mammalian CME
are, however, not fully understood. Here, we show
that the protein FCHSD2 is a major activator of actin
polymerization during CME. FCHSD2 deletion leads
to decreased ligand uptake caused by slowed pit
maturation. FCHSD2 is recruited to endocytic pits
by the scaffold protein intersectin via an unusual
SH3-SH3 interaction. Here, its flat F-BAR domain
binds to the planar region of the plasma membrane
surrounding the developing pit forming an annulus.
When bound to the membrane, FCHSD2 activates
actin polymerization by a mechanism that combines
oligomerization and recruitment of N-WASP to PI(4,5)
P2, thus promoting pit maturation. Our data therefore
describe a molecular mechanism for linking spatio-
temporally the plasma membrane to a force-gener-
ating actin platform guiding endocytic vesicle
maturation.
INTRODUCTION
Clathrin-mediated endocytosis (CME) is a process bywhich cells
internalize receptors, nutrients, lipids, and pathogens. CME is
characterized by the formation of dome-shaped membrane in-
vaginations covered by a polygonal clathrin cage termed cla-
thrin-coated pits (CCPs). A complex protein machinery works
alongside clathrin for initiation, growth, and scission of the
CCP. Despite being an ever present feature of CCPs (Ferguson
et al., 2009; Grassart et al., 2014), how the actin cytoskeleton af-
fects the process remains a matter of debate as the requirement
for the mechanical forces provided by this cytoskeletal compo-
nent seems to vary depending on cell type, membrane tension,
and cargo (Boulant et al., 2011; Fujimoto et al., 2000). Over the
years, multiple actin regulators have been described to partici-
pate in CME, including many BAR domain proteins (Daumke
et al., 2014; Merrifield and Kaksonen, 2014). The actin cytoskel-
eton at CCPs is organized as a densely branched network thatCell 174, 325–337, July 12, 2018 ª 2018 MR
This is an open access article undevolves from lateral patches around shallow pits to a ‘‘comet
tail’’ structure at the final stages of endocytosis (Collins et al.,
2011; Salisbury et al., 1980). Significantly, the actin cables on
CCPs are polymerized from the plasma membrane toward the
clathrin cage, supporting the idea that actin polymerization helps
to propel the CCP inward (Collins et al., 2011; Picco et al., 2015).
How this special actin organization arises and what the relative
contribution is of each one of the different actin regulators
described for CME remains largely unknown.
FCH and double SH3 domains protein 1 and 2 (FCHSD1 and
FCHSD2) are the mammalian homologs of the Drosophila
Nervous Wreck protein (Nwk). They are part of the BAR super-
family of dimeric membrane binding domains (https://www.
bar-superfamily.org). Nwk mutant flies are paralyzed under
non-permissive temperatures and show abnormal neuronal
morphology (Coyle et al., 2004). The Nwk protein interacts with
components of the CME and actin cytoskeleton machinery
(O’Connor-Giles et al., 2008; Rodal et al., 2008), but a detailed
understanding of its function, or of its mammalian homologs
FCHSD1/2, remains elusive. Here, we show that FCHSD2 is a
major activator of actin polymerization during CME. FCHSD2 is
recruited to CCPs by intersectin via an SH3-SH3 interaction
and localizes to the base of CCPs where it activates actin poly-
merization via N-WASP.
RESULTS
Vertebrate genomes encode two FCHSD proteins (FCHSD1 and
FCHSD2) that contain 4 distinct domains as shown in Figure 1A:
(1) an N-terminal F-BAR domain containing an atypical additional
coiled coil (CC) at its C terminus, (2) a first SH3 (src homology 3)
domain (SH3-1), (3) a second SH3 domain (SH3-2), and (4) a
C-terminal proline rich region (PRR). GST pull downs from brain
extracts using individual SH3 domains as bait confirmed that
FCHSD1/2, like its fly homolog Nwk (O’Connor-Giles et al.,
2008; Rodal et al., 2008), interact with N-WASP and intersectin
via its SH3-1 and SH3-2, respectively (Figure 1A). FCHSD1 is
generally expressed at lower levels than FCHSD2 (Uhlén et al.,
2015). Moreover, FCHSD1 is not detectable in the cells lines
we worked with (Hein et al., 2015). We therefore focused on
the main isoform FCHSD2.
FCHSD2 Is a Bona Fide CME Protein
The interaction of FCHSD2 and Nwk with CME components is
the primary indication of their participation in this processC Laboratory of Molecular Biology. Published by Elsevier Inc. 325
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
(legend on next page)
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(O’Connor-Giles et al., 2008; Rodal et al., 2008). To investigate
this matter further, we started by looking at the subcellular local-
ization and the dynamics of FCHSD2 during CME. Endogenous
FCHSD2 showed clear colocalization to clathrin punctae on the
plasma membrane (Figure 1B). Likewise, exogenously ex-
pressed FCHSD2-Venus formed dynamic punctae colocalizing
with the majority of mCherry-clathrin punctae (mCherry-clathrin
light chain A) (80% ± 7% measured over the period of 10 s,
n = 11 cells and Figure 1C). Live-cell imaging using a series of
CME components revealed that FCHSD2 recruitment to CCPs
occurred at a mid-to-late stage of pit maturation. FCHSD2 signal
appeared on CCPs after clathrin and intersectin and peaked
before the recruitment of dynamin and ARP3 (Figures 1D and
S1A; Video S1). Further confirming the participation of FCHSD2
in CME, FCHSD2 knockout (KO) cells displayed reduced trans-
ferrin uptake when compared with control cells (Figures 1E and
S1B). Interestingly, FCHSD2 KO cells compensate for slowed
endocytosis by increasing the amount of total and surface trans-
ferrin receptor (Figure S1C). This compensation phenomenon
has also been reported for cells depleted for PI3KC2a, epsin,
or dynamin (Ferguson et al., 2009; Messa et al., 2014; Posor
et al., 2013). Re-expression of FCHSD2 could partially rescue
the transferrin uptake defect (Figures 1E and S1B). We attribute
this partial rescue to variations in expression level within the pop-
ulation of rescued cells.
In several of our live cell experiments, we noticed the accumu-
lation of FCHSD2 punctae on the peripheral regions of moving
cells resembling adhesion sites. This led us to look at the rela-
tionship of FCHSD2 and integrins, a CME cargo associated
with focal adhesions (Ezratty et al., 2009). In cells simultaneously
expressing integrin b3, clathrinLC, and FCHSD2, we observed
the presence of dynamic FCHSD2 and clathrin punctae on the
majority of disassembling focal adhesions (Figure S2A;
Video S2). Accordingly, FCHSD2 KO and knockdown (KD) cells
showed significant impairment of active integrinß1 internaliza-
tion using a microscopy-based antibody-feeding assay (Fig-
ure S2B) and by flow cytometry (Figure S2C). In agreement
with the integrin uptake defect, FCHSD2 knockout led to a signif-Figure 1. FCHSD2 Is a Bona Fide CME Protein Responsible for a Majo
(A) Top: Scheme showing the domain organization of FCHSD proteins. Bottom: Im
from brain extracts using GST-tagged FCHSD1 and FCHSD2 SH3 domains. Low
(B) Immunofluorescence showing colocalization between endogenous FCHSD2
(C) TIRF image showing colocalization of FCHSD2 and clathrin. HeLa cells stably
(D) Left: Examples of the dynamics of FCHSD2 with different CME proteins. HeL
thrinLC, FusionRed-ITSN1L, FusionRed-Dynamin1, or mCherry-ARP3 and ima
recruitment. Events are pseudocolored to match graphs on the right. Right: Su
(n = 90, 48, 120, and 144 events for FCHSD2/clathrin, FCHSD2/ITSN1L, FCHSD2
shown in Figure S1A.
(E) Transferrin uptake assay by flow cytometry. Uptake measurements were no
rescence from at least 5,000 cells (n = 10, mean ± SD).
(F) Left: Kymographs of BSC1 AP2s2-GFP cells silenced for FCHSD2 or ARP3 and
in the case of ARP3 small interfering RNA [siRNA] cells). Right: Quantification of A
(n = 329, 870, and 227 events for control, FCHSD2 KD, and ARP3 KD, respectiv
(G) CCP morphological quantification for control HeLa and FCHSD2 KD and KO c
respectively).
(H) Transferrin uptake assay by flow cytometry comparing wild-type and FCHSD
described in the STAR Methods. Each value represents median fluorescence fro
***p > 0.001, **p > 0.01, *p > 0.01, one-way ANOVA with Tukey’s post hoc analy
See also Figures S1 and S2 and Videos S1 and S2 and Videos S1 and S2.icant reduction of cell migration asmeasured with a wound-heal-
ing assay (Figure S2D).
To further investigate the role of FCHSD2 on CME, we tested
the effect of FCHSD2 depletion on CME dynamics. For that, we
used BSC1 cells stably expressing GFP-tagged s2-adaptin
(AP2s2-GFP) (Ehrlich et al., 2004). As shown in Figure 1F, cells
depleted for FCHSD2 (Figure S1D) displayed longer CCP life-
times than control cells (44.9 s ± 21.7 s for FCHSD2 small hairpin
RNA [shRNA] cells versus 32.7 s ± 16.3 s for control cells,
mean ± SD). Morphological analysis of pits by electron micro-
scopy (EM) revealed that FCHSD2 KD and KO resulted in an
increased frequency of intermediate stage pits (U-shaped) at
the expense of terminal pits (U-shaped) (Figure 1G). In agree-
ment with the mid-to-late recruitment of FCHSD2 to CCPs (Fig-
ure 1D), we found no change on the frequency of early stage pits
(shallow pits) in FCHSD2-depleted cells. Taken together, our re-
sults show that FCHSD2 is a bona fide CME component whose
depletion leads to a kinetic defect in CME.
FCHSD2 Accounts for a Large Part of the Actin
Contribution to CME
The interaction of FCHSD2 with N-WASP (Figure 1A) suggests a
participation of this protein controlling actin polymerization dur-
ing CME. To understand what the relative importance of
FCHSD2 to the actin component of CME is, we decided to eval-
uate the CME phenotype in cells on which knockdown had been
performed for the essential subunit of the ARP2/3 complex,
ARP3 (Gournier et al., 2001). This strategy allowed us to look
specifically at the effect of branched actin, the main type of actin
structure formed during CME (Collins et al., 2011), without
affecting linear actin structures and circumventing typical actin
poisons that are very toxic andwere shown to only partially affect
the actin around CCPs (Collins et al., 2011). Cells with ARP3 KD
(Figure S1E) showed a substantial reduction (43%) in trans-
ferrin uptake (Figure 1H) and displayed a large increase in CCP
lifetimes with around a third of events lasting at least 180 s (the
entire duration of the movies) (Figure 1F). Similar to the effect
of FCHSD2 KO, ARP3 KD also led to an increase in surfacer Fraction of the ARP2/3 Contribution to CME
munoblots for N-WASP and Intersectin1 (ITSN1) from pull down experiments
er portion shows Coomassie staining of baits.
and clathrin heavy chain.
expressing FCHSD2-Venus and transfected with mCherry-clathrin light chain.
a cells stably expressing FCHSD2-Venus were transfected with mCherry-cla-
ged live by TIRF microscopy. Time zero was set as the peak of FCHSD2
mmary graphs for the timing of recruitment of FCHSD2 versus CME proteins
/Dynamin, and FCHSD2/ARP3, respectively). Full data including error bars are
rmalized as described in STAR Methods. Each value represents median fluo-
control cells. Kymographs generated from 120 s videos at 1 Hz (or 180 s at 1Hz
P2s2 lifetime for each condition. Only events longer than 20 s were considered
ely, mean ± SD).
ells (n = 100, 71, 101, and 70 CCPs for control, shRNA, KO(1), and KO(2) cells,
2 KO (2) cells silenced for ARP3. Uptake measurements were normalized as
m at least 5,000 cells (n = 6, mean ± SD).
sis. Scale bars, 10 mm in overviews, 5 mm in insets.
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Figure 2. Intersectin Recruits FCHSD2 to CCPs
(A) Lipid preference for FCHSD2 using liposome-pelleting assays. Liposome base mixture of PC, PE, and cholesterol was supplemented with PS or phos-
phoinositols (PIPs). After incubation with FCHSD2 BAR (F2B), the liposomes were pelleted by ultracentrifugation. P, pellet fraction; S, supernatant fraction.
Dashed horizontal line represents the level of protein alone that pellets under the experimental conditions (n = 3 experiments, mean ± SD).
(B) TIRF images of HeLa cells transfected with mCherry-clathrinLC and various GFP-tagged FCHSD2 truncation constructs. The domain arrangement for each
construct with their respective nomenclature is shown on the left.
(C) TIRF images of HeLa cells stably expressing FCHSD2-Venus andmCherry-clathrinLC transfected with a non-targeting control siRNA or siRNA for intersectins
(ITSN1+ITSN2).
(D) Quantification of the fraction of clathrin punctae colocalizing with FCHSD2 punctae on control and ITNS1+2 KD cells (n = 60, 75 cells for control siRNA and
ITSN1+2 siRNA respectively; mean ± SD). ***p > 0.001, t test.
Scale bars, 10 mm in overviews, 5 mm in insets.
See also Figure S3.transferrin receptor (increase of 37% ± 15% compared to wild-
type cells, n = 5 independent experiments with >5,000 cells).
Next, we compared the transferrin uptake of cells with single
and combined ARP3 and FCHSD2 depletion. In accordance
with FCHSD2 and ARP2/3 acting on CME via the same pathway
with ARP2/3 as a downstream factor, cells with combined ARP3
KD and FCHSD2KO showed a similar reduction in transferrin up-
take as cells with ARP3 KD alone (Figure 1H). An incomplete KD
may contribute to the small difference in transferrin uptake be-
tween ARP3 KD in wild-type and in FCHSD2 KO cells (p value =
0.04). Importantly, with ARP2/3 as a downstream factor of
FCHSD2, we could use the ARP2/3 contribution to CME as a
baseline to infer that FCHSD2 is a major contributor to the
ARP2/3 participation in CME. (Figure 1H).
FCHSD2 Is Recruited to CCPs by Intersectin via an SH3-
SH3 Interaction
CCP maturation is characterized by a cascade of phosphoinosi-
tide conversions that work as timekeepers of the process by
regulating the recruitment of individual CME components (He
et al., 2017; Posor et al., 2013). To identify if FCHSD2 has a pref-
erence for any specific phosphoinositide, and could explain its
recruitment to CCPs, we used a liposome-pelleting assay with
liposomes of specific compositions. As shown in Figure 2A,328 Cell 174, 325–337, July 12, 2018FCHSD2 binds preferentially to PI(3,4)P2 or PI(3,4,5)P3 contain-
ing liposomes. PI(3,4)P2 was recently shown to be a late CME
lipid generated by PI3KC2a (Posor et al., 2013). In agreement
with a potential role of PI(3,4)P2 on FCHSD2 function, KD of
PI3KC2a showed similar decrease in transferrin uptake as the
combined KD of PI3KC2a in FCHSD2 KO cells (Figure S3A).
However, KD of PI3KC2a had no significant effect on FCHSD2
recruitment to CCPs (Figure S3B), suggesting that phosphoino-
sitides are not primarily responsible for the recruitment of
FCHSD2 to CCPs but rather modulate its function after
recruitment.
To investigate which FCHSD2 domains are required for its
recruitment to CCPs, we expressed a series of truncation con-
structs in cells and evaluated their colocalization with clathrin
punctae. Only constructs that included the SH3-2 (FCHSD2 full
length and F2B12) localized to CCPs (Figure 2B). Expression of
the SH3-2 alone also formed punctae that colocalized with cla-
thrin, albeit to a lesser extent when compared to constructs
that also contained the F-BAR domain (Figure 2B). In addition,
expression of these truncation constructs revealed that, similarly
to what has been described for Nwk (Kelley et al., 2015), both
SH3 domains cooperate to autoinhibit FCHSD2. This autoinhibi-
tion avoids promiscuous membrane binding (Figure S3C, as
judged by formation of membrane protrusions and membrane
(legend on next page)
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binding in cells) and is predicted to be relieved when the SH3 do-
mains are occupied by their cognate binding proteins. Thus, our
data show that FCHSD2 is a bona fide CME component whose
recruitment to CCPs is dependent on its second SH3 domain.
Given the key role of FCHSD2 SH3-2 in the localization of
FCHSD2 to clathrin punctae, we tested if intersectin, a binding
partner of FCHSD2 SH3-2 (Figure 1A), is required for FCHSD2
recruitment to CCPs. We performed knockdown for both inter-
sectin isoforms (ITSN1/ITSN2) and quantified the colocalization
between clathrin punctae and FCHSD2. Accordingly, cells
silenced for ITSN1/2 showed a significant reduction of clathrin
punctae colocalizing with FCHSD2 when compared to control
cells (Figures 2C, 2D, and S3D). To further understand the rela-
tionship between intersectin and FCHSD2, we fine-mapped
this interaction. Previous work mapped the interaction between
the second SH3 of Nwk to a C-terminal fragment of dap160 con-
taining multiple SH3s (O’Connor-Giles et al., 2008; Rodal et al.,
2008). Taking this as a starting point, we tested the capacity of
each of the five SH3 domains of ITSN1 (SH3a-e) to interact
with FCHSD2 SH3-2 using GST pull downs. As shown in Fig-
ure 3A, the fourth SH3 domain of ITSN1 (SH3d) could pull
down FCHSD2 SH3-2. Isothermal titration calorimetry (ITC) re-
vealed a 248 nM (±75 nM) affinity (Kd) with a 1:1 stoichiometry
(Figure S4A). Thus, FCHSD2 is recruited to CCPs by intersectin
via an SH3-SH3 interaction.
SH3 domains generally bind short proline-rich sequences
rather than mediate domain-domain interactions (Kurochkina
and Guha, 2013). To understand how this unusual SH3-SH3
interaction occurs, we solved the crystal structure of the
FCHSD2 SH3-2/ITSN1 SH3d complex at 3.4 Å (Table S1). The
structure revealed tandem binding between the SH3 domains
with the canonical proline-binding interface of FCHSD2 SH3-2
interacting with the surface opposite to the proline-binding inter-
face of ITSN1 SH3d (Figures 3B, S4B, and S4C). The domains
form an extensive contact surface composed largely of hydro-
phobic residues and a few charge interactions (Figures 3C and
3D). To confirm the SH3-SH3 contacts as the bona fide biolog-
ical interface, we performed GST pull downs using a series of
mutants for both SH3 domains. Double mutants on FCHSD2
SH3-2 (Y576S+F607S or V622K+L623K) were required to
abolish the interaction to ITSN1 SH3d (Figure 3E). On the other
hand, single residue mutations on ITSN1 SH3d (I1078S,Figure 3. FCHSD2 Binds to Intersectin via an SH3-SH3 Interaction
(A) Coomassie stained gel of GST pull-down experiments using individual ITSN1
(B) Overview of the co-crystal structure of the complex FCHSD2 SH3-2 and ITSN
FCHSD2 SH3-2 is on top (in blue) and ITSN1-SH3d is on the bottom (in gold). O
FCHSD2 SH3-2 (in blue) and ITSN1 SH3d (in gold).
(C and D) Interaction surface of the FCHSD2 SH3-2/ITSN1-SH3d complex. Only t
blue) or ITSN1 SH3d (D, in gold).
(E and F) Top: Coomassie stained gels for pull-down experiments using individua
controls). Bottom: Quantification of the interaction of FCHSD2 SH3-2 mutants w
experiments, mean ± SD).
(G) Top: Confocal slice of HeLa cells transfected with FCHSD2-FusionRed plus m
Schematic explanation of the experiment. TOM20 TMD, TOM20 transmembrane
(H) Transferrin uptake assay by flow cytometry comparing cells expressing RFP
made from cells with high RFP signal. Results were normalized by the amount of
transfected cells. (n = 3 experiments with >5,000 gated cells, mean ± SD). ***p >
See also Figure S4 and Table S1.
330 Cell 174, 325–337, July 12, 2018I1078K, R1119A, or R1119E) could abolish the interaction with
FCHSD2 SH3-2 (Figure 3F). Additionally, mutation of residues
located on crystal contacts (FCHSD2 SH3-2 N613 and D583;
ITSN1 SH3d T1086) did not show any effect on binding (Figures
3E, 3F, and S4D).
Next, we set out to validate in cells the biological significance
of the FCHSD2 SH3-2/ITSN1 SH3d structure. In contrast to its
wild-type counterpart, expression of the FCHSD2 SH3-2 inter-
face mutant (Y576S+F607S) failed to localize to clathrin punc-
tae (Figure S4E). On the other hand, expression of wild-type
ITSN1 SH3d, but not the interface mutant counterpart
R1119E, resulted in a substantial reduction of FCHSD2 punctae
(Figure S4F). To further confirm the role of the FCHSD2 SH3-2/
ITSN1 SH3d crystal interface on the correct localization of
FCHSD2, we used the transmembrane domain of the mito-
chondrial translocase complex subunit TOM20 to mistarget
the ITSN1 SH3d to the mitochondria. In agreement with the
interface from the crystal structure, wild-type ITSN1 SH3d
could efficiently recruit FCHSD2 to the mitochondria while the
interface mutant ITSN1 SH3d R1119E could not (Figures 3G
and S4G). Finally, we tested the functional significance of the
FCHSD2 SH3-2/ITSN1 SH3d interaction. Expression of wild-
type ITSN1 SH3d acted as a dominant negative and could
inhibit transferrin uptake while the interface mutant counterpart
ITSN1 SH3d R1119E had a much smaller effect (Figure 3H).
Altogether, our results establish FCHSD2 as a CME protein
recruited by intersectin via an SH3-SH3 interaction, and the
ITSN1 SH3d overexpression can be used to interfere with
FCHSD2 function.
FCHSD2 Is a Strong Activator of Actin Polymerization in
the Presence of Membranes
Another important feature of FCHSD2 is its relationship with the
actin cytoskeleton via interaction of its first SH3 domain with the
ARP2/3 complex activator N-WASP (O’Connor-Giles et al.,
2008; Rodal et al., 2008) (Figure 1A). Activation of N-WASP via
interaction with SH3 domains has been described for many pro-
teins, including Nwk (Padrick and Rosen, 2010; Rodal et al.,
2008). To test the capacity of FCHSD2 to activate N-WASP,
we used a well-established in vitro assay (Doolittle et al., 2013)
in which the kinetics of actin polymerization can be followed by
monitoring the increase in the fluorescence of pyrene-labeledSH3 domains as baits to bind to FCHSD2 SH3-2.
1-SH3d. Electrostatic surface (left) and backbone trace (right) of the complex.
vals with PxxP represent canonical proline-rich peptide binding surfaces for
he residues within contact distance (<4 Å) are shown for FCHSD2 SH3-2 (C, in
l FCHSD2 SH3-2 (E) or ITSN1 SH3d (F) mutants of the interaction surface (and
ith ITSN1 SH3d (E) and ITSN1 SH3d mutants with FCHSD2 SH3-2 (F) (n = 3
itochondrially targeted wild-type or interface mutant of ITSN1 SH3d. Bottom:
domain. Scale bars, 10 mm in overviews, 5 mm in insets.
or RFP-ITSN1 SH3d (wild-type [WT] or interface mutant). Measurements were
surface transferrin receptor for each condition and against uptake for the RFP
0.001, **p > 0.01, one-way ANOVA with Tukey’s post hoc analysis.
Figure 4. FCHSD2 Activates Actin Polymer-
ization at CCPs
All actin polymerization reactions were performed
using 3 mM actin, 25 nM ARP2/3, and 50 nM
N-WASP. Liposomes were used at 12.5 mM. The
nomenclature for the fragments used is the same
as in Figure 2B.
(A) Actin polymerization experiments using
different FCHSD2 truncations in the absence (left)
and presence (right) of liposomes (Folch lipids,
extruded with 800 nm filters).
(B) Actin polymerization experiments using mu-
tants disrupting the proline-binding pocket of
SH3-1 and SH3-2. Full experiment including
additional controls and one extra set of mutants is
shown in Figure S5B.
(C) Actin polymerization experiments using lipo-
somes with different phosphatidylinositol compo-
sition. The full experiment including additional
controls is shown in Figure S5F.
(D and E) Actin polymerization experiments
comparing the activity of FCHSD2 with SNX9 (D)
and CIP4 in the presence of cdc42 (E).
See also Figure S5.actin. For all reactions, we used a minimal set of components
(actin, Arp2/3, and full-length N-WASP) where we could test
the effect of various purified FCHSD2 fragments. Without any
activator, this minimal set of components represents a baseline
of actin polymerization where N-WASP is largely inactive and the
majority of the signal comes from spontaneous actin nucleation
(Figure S5A).
In reactions containing only the minimal components, none of
the tested FCHSD2 fragments showed a significant increase of
actin polymerization when compared to the control reactions
(Figure 4A). In contrast, when liposomes where added to the re-
action, FCHSD2 fragments containing both the BAR domain and
the SH3-1 (F2B1 and F2B12) activated actin polymerization to
the same level as the positive control N-WASP-VCA (the
uninhibited fragment of N-WASP (Rohatgi et al., 1999) (Fig-
ure 4A). We further confirmed the requirement of the FCHSD2
SH3-1 domain for the activation of N-WASP by mutating the
canonical proline-binding site of the SH3-1 domain. Thesemuta-tions (Y478A/Y480A or P521A/Y524A)
rendered F2B12 incapable of increasing
actin polymerization while mutants for
the proline-binding site of FCHSD2
SH3-2 (Y576S/F607S or V622K/L623K)
still maintained full activation capacity
(Figures 4B and S5B). Titration of
FCHSD2 demonstrated that it is capable
of activating actin polymerization even at
substoichiometric concentrations (half-
maximal activity 6.3 nM in reactions
containing 50 nM N-WASP) (Figure S5C).
FCHSD2 SH3-1 alone could not sig-
nificantly increase actin polymerization
even at high concentrations (e.g., 1 mM)
(Figure S5D), suggesting an active roleof the interaction of FCHSD2 with the membrane on FCHSD2-
dependent activation of N-WASP.
There are two levels of N-WASP regulation: one level is where
the intramolecular autoinhibition of N-WASP is released by the
action of allosteric activators such as PI(4,5)P2 and cdc42 (Ro-
hatgi et al., 1999) and another level where oligomerization of
N-WASP by multivalent interactors greatly increases its affinity
for ARP2/3 complex (Padrick et al., 2008). The requirement of li-
posomes for efficient activation of N-WASP by FCHSD2 together
with the fact that FCHSD2 is a dimer (Figure S5E), and therefore
can bind two N-WASP molecules, suggests that FCHSD2 may
act on these two regulatory levels of N-WASP activation. To
test this possibility we used conditions that allowed us to differ-
entiate the contribution of FCHSD2 on each of these levels. As
PI(3,4)P2 is not an allosteric activator of N-WASP (Ma et al.,
1998), we could test the effect of FCHSD2-mediated N-WASP
oligomerization on membranes (using liposomes containing
PI(3,4)P2) and compare it to conditions where oligomerizationCell 174, 325–337, July 12, 2018 331
and recruitment to an allosteric activator would occur (using lipo-
somes containingPI(3,4)P2 andPI(4,5)P2). As shown in Figure 4C,
reactions with liposomes containing both PI(3,4)P2 and PI(4,5)P2
lipids showed maximum actin polymerization while reactions
with PI(3,4)P2 liposomes showed an intermediate level of
activation (Figures 4C and S5F). On the other hand, reactions
containing PI(4,5)P2 liposomes showed no increase in actin
polymerization (Figures 4C and S5F). These results show a
contribution of both oligomerization and allosteric activation in
FCHSD2-mediated N-WASP activation.
Our results in cells revealed FCHSD2 as a major activator of
ARP2/3-dependent actin polymerization during CME (Figure 1H).
To test this result in vitrowecompared the actin polymerizationac-
tivity of FCHSD2 with that of SNX9 and CIP4. These two F-BAR
domain proteins are proposed to activate N-WASP during CME
via direct activation of N-WASP (SNX9) (Yarar et al., 2007) or indi-
rectly via cdc42 (CIP4) (Fricke et al., 2009). As shown in Figure 4D,
FCHSD2displayedmuchhigheractinactivationactivity thanSNX9
with 90nM FCHSD2 still showing higher activation capacity than
560 nM SNX9. As expected, in the absence of cdc42, CIP4 failed
to activate actin polymerization (Figure S5G). In the presence of
GTPgS-loaded cdc42, CIP4 showed strong actin activation activ-
ity, however, still to a lower degree than FCHSD2 (Figure 4E).
Next, we decided to test the connection between both of the
features of FCHSD2: recruitment to CCPs and activation of actin
polymerization. As N-WASP activation leads to the recruitment
of the ARP2/3 complex to an existing actin filament, we used
the accumulation of ARP3 at dynamin spots as a reporter
for N-WASP activation. Confirming that FCHSD2 activates
N-WASP at CCPs, FCHSD2KOcells showed a significant reduc-
tion of ARP3 punctae colocalizing with dynamin in a live cell im-
aging experiment (Figure S5H). Taken together, these results
show that FCHSD2 is a major activator of actin polymerization
via N-WASP at CME sites.
FCHSD2 Localizes to the Planar Membrane
around CCPs
The actin cytoskeleton forms a distinctive structure at CME sites
(Collins et al., 2011). To understand how FCHSD2 contributes to
the formation of this structure, we examined where on CCPs
FCHSD2 was localized. We started by probing the relative
Z-displacement of FCHSD2 during CCP lifetime. For this, we
compared the fluorescence profiles of FCHSD2, AP2 (AP2s2),
and dynamin1 captured sequentially in total internal reflection
fluorescence (TIRF) and widefield (WF). Using this imaging para-
digm, proteins located in budding clathrin vesicles lose their
signal on the TIRF channel (as the evanescent field is only
100 nm in depth) while maintaining it for a few more seconds
on the WF channel. In contrast, if a protein stays on the plasma
membrane during the whole lifetime of the CCP, the fluores-
cence decays at the same time for both TIRF and WF channels
(Figure 5A). As expected for their established roles in CME,
AP2 profiles showed a delayed fluorescence decay on the WF
channel (i.e., AP2 buds off with the clathrin-coated vesicle), while
dynamin fluorescence decayed at the same time on both chan-
nels (i.e., dynamin stays on the plasma membrane) (Figure 5B).
FCHSD2 signal decayed at the same time in both TIRF and WF
channels (Figure 5B), suggesting FCHSD2 is not located on or332 Cell 174, 325–337, July 12, 2018around the clathrin cage, but rather stays close to the plasma
membrane during CME.
To further address the localization of FCHSD2 on CCPs, we
imaged FCHSD2 and AP2 with stimulated emission depletion
(STED) super-resolution microscopy. While AP2 showed a com-
plete colocalization with clathrin, FCHSD2 formedmultiple punc-
tae arranged in a semi-circle (sometimes a circle) around CCPs
(Figures 5C and 5D). To further confirm the position of FCHSD2
on CCPs, we used 3D STED, which allows increased resolution
imaging at the Z plane (albeit at the expense of lower resolution
at XY). The orthogonal (XZ) view of FCHSD2 and clathrin by 3D
STED confirmed that FCHSD2 is localized around and at the
plasma membrane side of CCPs (Figure 5E). In agreement with
FCHSD2 being localized out of the boundaries of the budding
CCP, FCHSD2 was not present in purified CCVs (Figure S6A).
F-BAR domains are elongated, slightly curved, dimeric mem-
brane-binding domains. The intrinsic shape of these domains
determines the curvature of the membrane they are bound to
(Qualmann et al., 2011). As such, expression of most F-BAR do-
mains generates inward tubules in cells (Boucrot et al., 2012;
Frost et al., 2008). In contrast, expression of FCHSD2 (and
Nwk) F-BAR domain generates large numbers of filopodia-like
cellular protrusions (Figure S6B) (Kelley et al., 2015). Interest-
ingly, we observed that overexpressed FCHSD1/2 F-BAR do-
mains coat the whole cellular membrane and not only the
protrusions it induces (Figure S6B, inset). The data we present
here shows that FCHSD2 is concentrated on a region of the
membrane that is primarily flat, suggesting that FCHSD2
F-BAR is either distinctly shaped or has a distinct mode of bind-
ing to membranes. To investigate this atypical behavior, we
started by checking the curvature preference of FCHSD2
in vitro. For that, we adapted the nanoparticle tracking analysis
(NTA) system (Dragovic et al., 2011) to determine curvature pref-
erences of protein domains to liposomes using low protein con-
centrations and avoiding curvature generation artifacts (A.C.,
L.A.-S., and H.T.M., unpublished data). This method is able to
distinguish to which liposome sizes a particular protein binds
within a population of heterogeneously sized liposomes. In
agreement with its cellular localization, NTA shows that FCHSD2
binds preferentially to larger liposomes (Figure 5F).
To understand the molecular basis of FCHSD2 curvature
preference, we used single particle CryoEM to determine the
structure of the FCHSD2 F-BAR domain + SH3-1 domain
(F2B1) (Figures S6C and S6D). We obtained a 9.2 Å reconstruc-
tion (Figure S6E) that reveals a largely flat F-BAR with densities
on its tips compatible with the SH3-1 domains (Figures 5G
and 5H). Furthermore, our FCHSD2 F-BAR map shows similar-
ities with the crystal structure of the FES F-BAR (PDB: 4DYL,
no associated publication), which is also a flat F-BAR domain
(Figure S6F). Altogether, our results show that FCHSD2 stays
on the surrounding plasma membrane during CME and binds
to membranes via its atypical, flat F-BAR domain.
DISCUSSION
CME and Its Multiple Actin Regulators
The functional connection between the actin cytoskeleton and
CME has been a matter of controversy for more than a decade.
Figure 5. FCHSD2 Localizes to the Plasma Membrane Side of CCPs
(A) Sequential widefield (WF) and TIRF imaging of endocytic proteins allows the distinction between proteins that stay on the membrane and proteins that move
away from the membrane.
(B) Results for AP2, dynamin, and FCHSD2 using the experimental paradigm explained in (A). Image series of representative events generated from videos at
0.5 Hz. (n = 54, 51, and 53 events for AP2, dynamin, and FCHSD2 respectively, mean ± SEM).
(C–E) Comparative localization of AP2 and FCHSD2 with CCPs by confocal (C), STED (D), and 3D STED (E) microscopy. Stable HeLa cells for AP2s2-GFP and
FCHSD2-Venus cells were stained with anti-GFP and anti-Clathrin antibodies. Cartoon representations of the views are shown on the right hand side of super
resolution images. Scale bars, 0.25 mm.
(F) Curvature preference of FCHSD2 BAR by nanoparticle tracking analysis (NTA). Graph showing the size distribution of the total liposome population and the
FCHSD2 BAR-sfGFP bound subpopulation. Total population distribution is measured by tracking particles diffracting light while FCHSD2 bound population is
measured by tracking particles emitting light from GFP excitation. FCHSD2 BAR-sfGFP added at 1 nM (n = 3 experiments, mean ± SD).
(G and H) Single particle cryoEM of F2B1 (FCHSD2 F-BAR+SH3-1). (G) 3D reconstruction from 30,207 particles. (H) The densities at the tip of the 3D map are
compatible with an SH3 domain. In magenta is a surface representation of the FCHSD2 SH3-1 NMR structure (PDB: 2DL5).
See also Figure S6.While this relationship is well established in yeast (Merrifield
and Kaksonen, 2014), its importance in mammalian systems
seems to be context- or cell-dependent (Boulant et al., 2011;
Fujimoto et al., 2000). Nonetheless, a growing body of evidence
supports the idea that actin is an intrinsic component of
mammalian CCPs (Ferguson et al., 2009; Grassart et al.,2014) and modulates the effectiveness of CCP budding. More-
over, the intimate connection between CCPs and the actin
cytoskeleton is further reinforced by a large number of CME
proteins showing actin-related activities such as HIP1/HIP1R,
the long isoforms of ITSN1/2 and notably, multiple F-BAR pro-
teins (Daumke et al., 2014; McMahon and Boucrot, 2011;Cell 174, 325–337, July 12, 2018 333
Figure 6. Model for FCHSD2 Function in CME
See text for details.Qualmann et al., 2011). In which conditions these proteins are
required, what their relative contribution is, and how they are
organized to optimize the mechanical action of the actin cyto-
skeleton during CME remains unclear.
The unique position of FCHSD2 at the planar membrane re-
gion surrounding CCPs suggests a possible explanation for
the apparent redundancy of actin regulators during CME. By
coordinating the position and the timing of each actin regu-
lator, cells would be able to change the strength and direction
of actin mechanical forces during multiple stages of vesicle
maturation. It is reasonable to assume that the multiple geom-
etries acquired by the clathrin coat and the underlying budding
membrane as CCPs mature would benefit from distinct force
vectors. This possibility is supported by a recent work showing
that, at least in yeast, different types of actin network are
required during different stages of endocytosis (Picco et al.,
2018). In addition to the distribution of force vectors during
CME, the contribution of each individual actin regulator may
also be tissue- and cargo-dependent or be involved in the
transport of vesicles post scission. Future efforts to access
the spatiotemporal organization of actin regulators in
multiple cells during CME would be necessary to test these
hypotheses.334 Cell 174, 325–337, July 12, 2018A Model for FCHSD2 Regulation and Function
In this study, we moved away from using actin polymerization
inhibitors because of their toxic effects in cells. Using the inacti-
vation of the ARP2/3 complex, we could obtain a consistent
baseline for the contribution of branched actin polymerization
during CME and determine that FCHSD2 is responsible for a
large part of this contribution (Figure 1H). We cannot rule out
that ARP3 KD can have indirect effects on CME by affecting,
for example, membrane tension. Nonetheless, if these side ef-
fects occured, they would imply an even higher importance of
FCHSD2 to the ARP2/3 contribution to CME. The relative impor-
tance of FCHSD2 to CME was further reinforced by the reduced
recruitment of ARP3 to CCPs in FCHSD2 KO cells (Figure S5H),
and a similar contribution measured by transferrin uptake. In
addition, FCHSD2 activated actin polymerization via N-WASP
in vitro more efficiently than the F-BAR proteins we tested (Fig-
ures 4 and S5).
The timing of FCHSD2 recruitment combined with the pheno-
types of FCHSD2 KO cells (increased CCP lifetimes and the
accumulation of U-shaped pits) show that FCHSD2 has a kinetic
role at the intermediate stage of CCP maturation, when the tran-
sition from a shallow invagination to a constricted pit ready for
scission occurs. During this transition, the actin cytoskeleton at
CCPs evolves into a cone-shaped, densely branched network
with its origin at the flat region around CCPs (Collins et al.,
2011). The position and function of FCHSD2 strongly suggests
that this protein is involved in the generation of this actin
structure.
Our data suggest that recruitment and activation of FCHSD2
are stepwise events. While the presence of FCHSD2 in CCPs
is dependent exclusively on intersectin, FCHSD2 activation
seems to be dependent on the phosphoinositide PI(3,4)P2.
Further supporting a stepwise cascade of events, both SH3 do-
mains participate in FCHSD2 autoinhibition (Figure S3C). We
believe that this uncoupling allows cells to spatiotemporally con-
trol FCHSD2 activation. A recent work elegantly showed that in-
tersectin migrates to the edge of the clathrin coat as CCPs
mature (Sochacki et al., 2017). Therefore, we hypothesize that
FCHSD2 is recruited by intersectin and is kept in an inhibited/
low activity state until it reaches the edge of the CCP, where
the accumulation of PI(3,4)P2 recruits FCHSD2 to the flat mem-
brane triggering actin polymerization.
Taking all this information into account, we propose the
following model for FCHSD2 function (Figure 6). After CME
initiation, FCHSD2 is recruited to CCPs by intersectin via an
SH3-SH3 interaction and intersectin-FCHSD2 complexes accu-
mulate at the edge of CCPs. The flat FCHSD2 F-BAR domain
and presence of the late phosphoinositide PI(3,4)P2 drives the
binding of FCHSD2 to the planar region apposed to CCPs
and allows it to activate actin polymerization. The FCHSD2-
dependent actin structure around CCPs helps the efficient
invagination of the maturing pit. Finally, other CME players
(both actin and actin-independent) take over and ensure the
completion of the process.
The Rise of Non-canonical F-BARs
The BAR superfamily is characterized by the presence of
an elongated, dimeric membrane-binding domain (Qualmann
et al., 2011). The superfamily is further subdivided into N-BAR,
F-BAR, and I-BAR families. While this division is primarily based
on the homology between these domains, the initial crystal
structures described suggested that this classification also
implied a shape of the molecule and by consequence its curva-
ture preference (Frost et al., 2008; Henne et al., 2007; Qualmann
et al., 2011; Rao and Haucke, 2011). While for N-BAR and I-BAR
proteins this correlation still holds true, the F-BAR family has
shown to be far more flexible regarding its curvature preference.
The first non-canonical F-BAR characterized were the SRGAP
proteins that were shown to generate large filopodia when ex-
pressed in cells (Coutinho-Budd et al., 2012). The crystal struc-
ture of SRGAP F-BAR domain revealed an inverted F-BAR,
with its lipid binding sites situated in the convex rather than the
concave surface (Sporny et al., 2017). Similarly, the structure
of the FES F-BAR domain revealed a flat BAR domain (PDB:
4DYL, no associated publication). The CryoEM map we present
here adds to the list of unusual F-BARs and supports the idea of
the F-BAR domain as a module used by evolution to recognize
multiple curvatures.
Why would cells need a BAR domain to recognize a flat
membrane? The FCHSD2 F-BAR is a large domain (467 aa),
and one could argue that a small globular domain, such as a
PH domain, could do the same job. We reason that a flat
BAR domain with multiple binding sites scattered over its
length provides a structural framework to ensure that FCHSD2
binds only to the planar membrane around the CCPs rather
than competing for other phosphoinositol lipids on the curved
regions of the budding membrane. Small globular membrane
binding domains are exquisite at recognizing specific lipids.
However, with a footprint of only a few lipid headgroups, small
domains on their own are possibly unable to read the long-
range differences that distinguish a flat membrane from a
curved one.
Beyond CME
Besides its CME role, intersectin has been described to partici-
pate in a series of other processes including other endocytic
routes, exocytosis, and viral entry (Herrero-Garcia and O’Bryan,
2017). The intimate connection between FCHSD2 and intersec-
tin and the affinity of FCHSD2 to the pivotal signaling phosphoi-
nositol PI(3,4,5)P2 opens the possibility that the combined actin
remodeling capacity of these proteins are used in processes
other than CME.
Conclusion
In conclusion, our work places FCHSD2 as a pivotal player
regulating actin polymerization during CME. The unique posi-
tion of FCHSD2 on the planar membrane around CCPs is, to
our knowledge, the first description of a CME-specific mamma-
lian protein localized on a region other than the clathrin coat or
the neck of the CCPs. The mechanism we describe for
FCHSD2 illustrates how cells link in space and time the forma-
tion of CCPs and the reorganization of the cortical actin
cytoskeleton during mammalian endocytosis. These findings
also provide a mechanistic framework that may be appli-
cable to other membrane bending events involving the actin
cytoskeleton.STAR+METHODS
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Picco, A., Mund,M., Ries, J., Nédélec, F., and Kaksonen, M. (2015). Visualizing
the functional architecture of the endocytic machinery. eLife 4, 1039.
Picco, A., Kukulski, W., Manenschijn, H.E., Specht, T., Briggs, J.A.G., and
Kaksonen, M. (2018). The contributions of the actin machinery to endocytic
membrane bending and vesicle formation. Mol. Biol. Cell. Published online
April 10, 2018. https://doi.org/10.1091/mbc.E17-11-0688.
Posor, Y., Eichhorn-Gruenig, M., Puchkov, D., Schöneberg, J., Ullrich, A.,
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Antibodies
Rabbit polyclonal anti-FCHSD2 (F2B1) This paper N/A
Rabbit polyclonal anti-FCHSD2 (F2S2) This paper N/A
Rabbit polyclonal anti-ITSN1 (Clone S750) A grift from Thomas Sudhof
(Stanford, USA)
N/A
Rabbit polyclonal anti-GFP Abcam Cat# Ab290
Mouse monoclonal anti-integrinß1 (clone 12G10) Santa cruz biotechnology Cat# Sc-59827
Anti-ARP3 (Clone FMS338) Sigma-Aldrich Cat# A5979
Mouse monoclonal anti-PI3KC2a (clone 17) BD biosciences Cat# 611046
Rabbit monoclonal anti-Nwasp Abcam Cat# Ab126626
Mouse monoclonal anti-CHC (clone x22) Thermo Fisher scientific Cat# MA1-065
Mouse monoclonal Anti transferrin receptor (clone H68.4) Thermo Fisher scientific Cat# 13-6800
Mouse monoclonal Anti-adaptin beta1,2 (clone 100/1) Thermo Fisher scientific Cat# MA1-25065
Bacterial and Virus Strains
E.coli Rosetta (DE3) Novagen Cat# 70954
Chemicals, Peptides, and Recombinant Proteins
Fibronectin Sigma-Aldrich Cat# F1141
Total Brain extract lipids (Folch) Sigma-Aldrich Cat# B1502
Total Brain extract lipids (Folch) Avanti polar lipids Cat# 131101P
2-Oleoyl-1-palmitoyl-sn-glycero-3-phosphocholine (PC) Sigma-Aldrich Cat# 42773
3-sn-Phosphatidylethanolamine (PE) Sigma-Aldrich Cat# P7693
1,2-Diacyl-sn-glycero-3-phospho-L-serine (PS) Sigma-Aldrich Cat# P6641
Cholesterol Sigma-Aldrich Cat# 47127
PI(3)P Avanti polar lipids Cat# 850150
PI(4)P Avanti polar lipids Cat# 850158
PI(5)P Avanti polar lipids Cat# 850152
PI(3,4)P2 Avanti polar lipids Cat# 850183
PI(4,5)P2 Sigma-Aldrich Cat# 840046
PI(3,4,5)P3 Avanti polar lipids Cat# 850166
ARP2/3 complex Cytoskeleton inc Cat# RP01P
Pyrene labeled actin Cytoskeleton inc Cat# AP05
Transferrin Alexa fluor 488 Thermo Fisher scientific Cat# T13342
In-Fusion HD cloning kit Clontech Cat# 638911
Gateway LR clonase Thermo Fisher scientific Cat# 11789100
Gateway BP clonase Thermo Fisher scientific Cat# 11791100
Lipofectamine LTX Thermo Fisher scientific Cat# A12621
Lipofectamine RNAiMax Thermo Fisher scientific Cat# 13778150
Deposited Data
FCHSD2 SH3-2/ITSN1 SH3d crystal structure This paper PDB: 6GBU
FCHSD2 F-BAR + SH3-1 CryoEM map This paper EMDB: EMD-4371
Experimental Models: Cell Lines
HeLa cells ATCC Cat# CCL2
HeLa FCHSD2 KO (clone 1) This study N/A
HeLa FCHSD2 KO (clone 2) This study N/A
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Hek293T cells ATCC Cat# CRL-3216
Flp-in T-Rex HeLa cells A gift from Dr. Stephen Taylor
(U. Manchester, UK)
N/A
BSC1 cells stably expressing the adaptin s2 subunit
of the AP2 complex
Ehrlich et al., 2004 N/A
HeLa cells stably expressing the adaptin s2 subunit
of the AP2 complex
This study N/A
Sf9 cells ATCC Cat# CRL-1711
Oligonucleotides
ITSN1 siRNA (esiRNA) Sigma-Aldrich Cat# EHU102031
ITSN2 siRNA (esiRNA) Sigma-Aldrich Cat# EHU064971
ARP3 siRNA (esiRNA) Sigma-Aldrich Cat# EHU107121
PI3KC2a siRNA pool Origene Cat# SR303516
Recombinant DNA
pcDNA5/FRT/TO/Venus Gateway destination vector A gift from Jonathon Pines
(Gurdon institute, Cambridge, UK)
N/A
pCDNA5/FRT/TO-FCHSD2-Venus This study N/A
FCHSD2 shRNAs Sigma-Aldrich TRCN0000147537, TRCN0000147035,
TRCN0000148919
pFUW-AP2s2-GFP Ehrlich et al., 2004 N/A
pSpCas9(BB)-2A-GFP (PX458) Ran et al., 2013 Adgene (Cat# 48138)
PX458-FCHSD2_gRNA2 (ACTTCAAGCCAAACATCAAG) This study N/A
pLenti6/V5-Dest Thermo Fisher scientific Cat# V49610
pLenti6-FCHSD2 This study N/A
pOPINS (N-terminal His-SUMO tag) Oxford protein
production facility
N/A
pOPINS-FCHSD2 FCHSD2 BAR (F2B: aa1-468) This study N/A
pOPINS-FCHSD2 BAR + SH3-1 (F2B1: aa1-530) This study N/A
pOPINS-FCHSD2 BAR + SH3-1 + SH3-2 (F2B12: aa1-629) This study N/A
pOPINS-FCHSD2 SH3-1 (aa469-530) (wt and mutants:
Y478A+Y480A; P521A/Y524A)
This study N/A
pOPINS-FCHSD2 SH3-2 (aa568-629) (wt and mutants:
Y576S+F607S; V622K+L623K)
This study N/A
p7x- FCHSD2 BAR-sfGFP (C-terminal sfGFP-6xHis) This study N/A
pCI-FCHSD2 - EGFP This study N/A
pCI-FCHSD2 - FusionRed This study N/A
pCI-FCHSD2 FCHSD2 BAR - EGFP (F2B-GFP) This study N/A
pCI-FCHSD2 BAR + SH3-1 - EGFP (F2B1-GFP) This study N/A
pCI-FCHSD2 BAR + SH3-1 + SH3-2 - EGFP (F2B12-GFP) This study N/A
pCI-EGFP-FCHSD2 SH3-1 (GFP-F2S1) This study N/A
pCI-EGFP-FCHSD2 SH3-2 (GFP-F2S2) (wt and
Y576S+F607S)
This study N/A
pCI-RFP-ITSN1 SH3d (wt and R1119E) This study N/A
pCI MitoGFP-ITSN1 SH3d (wt and R1119E) This study N/A
pGEX6P2- FCHSD2 SH3-1 (aa469-530) (N-terminal GST) This study N/A
pGEX6P2- FCHSD2 SH3-2 (aa568-629) (N-terminal GST)
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pGEX6P2- ITSN1 SH3a (aa740-806) (N-terminal GST) This study N/A
pGEX6P2- ITSN1 SH3b (aa913-971) (N-terminal GST) This study N/A
pGEX6P2- ITSN1 SH3c (aa10021060) (N-terminal GST) This study N/A
pGEX6P2- ITSN1 SH3d (aa1076-1138) (N-terminal GST)
(WT and mutants:I1078S; I1078K; R1119A; R1123E;
T1086A)
This study N/A
pGEX6P2- ITSN1 SH3e (aa1155-1214) (N-terminal GST) This study N/A
pOPINS-ITSN1-SH3d (aa1076-1138) This study N/A
pOPINS-cdc42 This study N/A
pOPINS-CIP4 This study N/A
pOPINS-SNX9 This study N/A
pOPINS-N-WASP VCA (aa385-501) This study N/A
pACEBAC1-N-WASP This study N/A
mCherry-ClathrinLC A gift from Dr. Christien Merrifield
(I2BC, Paris, France)
N/A
mCherry-ARP3 A gift from Dr. Christien Merrifield
(I2BC, Paris, France)
N/A
FusionRed-ITSN1L This study N/A
FusionRed-Dynamin1 This study N/A
Integrinb3-BFP This study N/A
Software and Algorithms
ImageJ (Fiji) Schindelin et al., 2012 https://fiji.sc/
Nanosight NTA software version 3.1 Malvern https://www.malvernpanalytical.com
MOSFLM Battye et al., 2011 N/A
Scala Evans, 2006 N/A
Phaser-MR McCoy, 2007 N/A
Coot Emsley et al., 2010 N/A
REFMAC Murshudov et al., 2011 N/A
CCP4MG McNicholas et al., 2011 N/A
Relion Scheres, 2012 N/A
Chimera Pettersen et al., 2004 N/A
Graphpad Prism 6.0 N/A https://www.graphpad.comCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents should be directed to and will be fulfilled by the Lead Contact, Leonardo
Almeida-Souza (lalmeida@mrc-lmb.cam.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
HeLa (female), and BSC1 (unknown gender) cells were cultured in MEM (Thermo Fisher scientific) while HEK293T (female) were
cultured in DMEM (Thermo Fisher scientific). In all cases media was supplemented with 10% fetal bovine serum (FBS) and 1 mM
GlutaMAX-I (Thermo Fisher scientific).
HeLa Flp-in T-Rex (female) stables cells were selected and kept in MEMmedia supplemented with 10% fetal bovine serum (FBS)
and 1 mM GlutaMAX-I (Thermo Fisher scientific) and 150 mg/ml hygromycin B (Thermo Fisher scientific) and 5 mg/ml blasticidin S
(Thermo Fisher scientific).
For all microscopy experiments, HeLa cells were cultured in fibronectin-coated dishes (20 mg/ml, 2-4 h). We observed that the
fibronectin coating reduces the amount of clathrin plaques in HeLa cells and allows the visualization of individual endocytic events.
A more detailed explanation of this finding will be published elsewhere (L.A.-S. and H.T.M., unpublished data).e3 Cell 174, 325–337.e1–e7, July 12, 2018
METHODS DETAILS
FCHSD2 Antibodies
The rabbit polyclonal FCHSD2 antibodies used throughout this study were produced by David’s Biotechnologie (Germany) using re-
combinant F2B1 (used for immunoblots) or FCHSD2 SH3-2 (used for immunofluorescence). None of the FCHSD2 antibodies
commercially available displayed a reduction of FCHSD2 in knockdown or knockout cells by western blot or immunofluorescence.
Constructs
All constructs for mammalian expression and GST fusion expression were made by Gateway recombination (Thermo Fisher scien-
tific). cDNA reference sequences used are: FCHSD2 (human NM_014824), Fchsd1 (mouse NM_175684), ITSN1L (human,
NM_003024), Dynamin1 (Bovine NM_001076820), Integrin b3 (human, NM_000212), CIP4 (human, NM_004240), SNX9 (Human,
NM_016224), cdc42 (Human, NM_001791). For protein production in E. coli using 6xHis-SUMO tag, PCR fragments were cloned
in pOPINS via In-Fusion recombination (Clontech). For N-WASP purification in baculovirus, the coding sequence of N-WASP (mouse
NM_028459) was amplified using an oligo including an N-terminal 6xHis tag and cloned in pACEBAC1 via In-Fusion recombination
(Clontech). FCHSD2 shRNA constructs were purchased from Sigma (TRCN0000147537, TRCN0000147035, TRCN0000148919).
Boundaries for constructs used are as follows: FCHSD2 BAR (F2B: aa1-468); FCHSD2 BAR + SH3-1 (F2B1: aa1-530); FCHSD2
BAR + SH3-1 + SH3-2 (F2B12: aa1-629); FCHSD2 SH3-1 (aa469-530); FCHSD2 SH3-2 (aa568-629); ITSN1 SH3a (aa740-806);
ITSN1 SH3b (aa913-971); ITSN1 SH3c (aa10021060); ITSN1 SH3d (aa1076-1138); ITSN1 SH3e (aa1155-1214); N-WASP VCA
(aa385-501). Mito-ITSN1 constructs were generated by site directed mutagenesis by adding the 33 first aminoacids of TOM20
(MVGRNSAIAAGVCGALFIGYCIYFDRKRRSDPN) to the N terminus of the GFP-ITSN1 constructs. Constructs mCherry-ClathrinLC
and mCherry-ARP3 were a gift from Dr. Christien Merrifield (Institut de Biologie Intégrative de la Cellule - I2BC, Paris, France).
The AP2s2-GFP construct was a gift from Dr. Tomas Kirchhausen (Harvard, Boston, USA). The pcDNA5/FRT/TO/Venus Gateway
destination vector was a gift from Jonathon Pines (The Gurdon Institute, Cambridge, UK). pSpCas9(BB)-2A-GFP (PX458) was a
gift from Feng Zhang (Addgene plasmid # 48138).
Generation of stable cell lines
FCHSD2-Venus HeLa Flp-in T-Rex cells were generated following the protocol for the generation of Flp-in expression cells (Thermo
Fisher scientific) using full length FCHSD2 cloned into the destination vector pcDNA5/FRT/TO/Venus. Transgene expression was
induced by addition of 1mg/ml tetracycline. HeLa AP2s2-GFP stable cells were generated by transfecting the vector pFUW-
AP2s2-GFP followed by selection with G418 (500mg/ml) for two weeks. A low expressing clone was selected for experiments.
To generate HeLa FCHSD2 CRISPR/Cas9 knockouts, cells were transfected with 3 different gRNAs (AGCATCATGCAGC
CGCCGCC, ACTTCAAGCCAAACATCAAG, CAGAAGAAGGCTGCTATTGA) cloned into pX458 (Ran et al., 2013). Individual clones
were selected by limiting dilution and screed for FCHSD2 expression by western blot. The second gRNA yielded a few complete
knockout clones. Two of them were selected for further experiments.
FCHSD2 knockdown cell lines were generated by lentiviral transduction of HeLa and BSC1 cells with shRNA constructs and
selectedwith puromycin (2 mg/ml for HeLa, 10 mg/ml for BSC1). The FCHSD2 rescue cell line was generated by lentivirus transduction
of the CRISPR KO cells with a virus encoding the full-length untagged FCHSD2 cloned in pLenti6/V5-Dest (Thermo Fisher scientific)
and selected with blasticidin (10 mg/ml).
For siRNA knockdown, cells were transfected with Lipofectamine RNAiMax (Thermo Fisher scientific) following manufacturer in-
structions. Experiments were performed 72 h after transfection.
Cell preparation for microscopy
For TIRF and Spinning disk imaging, cells were seeded in 35mmglass-bottom dishes (MatTek) and transfected after 24 h. Cells were
imaged without fixation for single pictures and time-lapse videos. For STED microscopy, HeLa FCHSD2-Venus and HeLa AP2s2-
GFP cells were seeded in 13 mm glass coverslips, fixed with PFA (4%, 15 min, Ice), washed with PBS and stained with anti-
GFP(1:100) and anti-CHC (1:50) overnight at 4C, followed by PBS washes (5x 5 min) and a 2 h incubation with secondary antibodies
at 1:100 dilution. After secondary incubation, coverslips were washed with PBS (5x 5 min) and mounted using ProLong diamond
(Thermo Fisher scientific). Slides were left at room temperature for 24-48 h to cure the mountant before imaging.
Microscopy
TIRF images were acquired in a Nikon N-STORM microscope controlled by Nikon Elements software using a 100x objective. STED
and confocal images were acquired in a Leica TCS SP8 X gated STED microscope controlled by Leica Application Suite X (LAS X)
software equipped with a tunable pulsed white light laser for excitation and 592 nm and 660 nm depletion lasers using 100x or 63x
objectives. SIM images were acquired in ZeissElyra S.1 and processed using the Zeiss acquisition software ZEN using a 63x objec-
tive. Spinning disk images were acquired using a Nikon TE2000 microscope equipped with a CSU-X1 spinning disk confocal head
(UltraVIEW VoX, Perkin-Elmer) controlled by Volocity using a 63x objective.Cell 174, 325–337.e1–e7, July 12, 2018 e4
Live cell imaging
For FCHSD2 dynamics with CME components, TIRF movies were taken at 1 frame/s using 100-300 ms exposure times. For CCP
lifetime with BSC1 cells expressing AP2s2-GFP, spinning disk movies were taken at 0.5 frame/s using 600 ms exposure times.
For dynamic colocalization of dynamin and ARP2/3, TIRF movies were taken at 0.5 frame/s using 300 ms exposure times. For
the dynamics of FCHSD2, clathrin and integrins, TIRF movies were taken at 3 frames/min using 300 ms exposure times.
Image analysis
All images were analyzed using ImageJ (Schindelin et al., 2012). In brief, analyses were done as follows:
CCP dynamics:
Dynamic events were identified by selecting brightest spots from a standard deviation projection using 50 frames in the middle of
movies. For every selected event, maximum fluorescence for the reference channel (i.e., FCHSD2) was identified and the fluores-
cence profile for both channels of 50 frames on each side of themaximum fluorescencewas selected. Tracesweremanually selected
for events showing fluorescence profiles compatible with typical endocytic events. The use of a common reference point for all traces
ensures the fluorescence profiles are aligned and allows direct comparison and averaging of all events. Curves were smoothed and
normalized for display.
Colocalization:
Fluorescence maxima on both channels identifying clear spots were selected from images and converted into binary spots. The
spots for the reference channel were expanded to 3x3 pixels and colocalizing spots were identified by image subtraction.
Widefield/TIRF fluorescence decay:
Events with clear signal on both widefield and TIRF channels were identified by visual inspection of movies and selected by drawing a
8x8 pixels box (0.1 mm/pixel) around them. Using the first frame where the TIRF signal disappears as reference, fluorescence profiles
of 20 frames on each side of this reference point were selected. The use of a common reference point for all traces ensures the fluo-
rescence profiles are aligned and allows direct comparison and averaging of events.
CCP Lifetime:
Dynamic events were identified by selecting brightest spots from a standard deviation projection using 20 frames in the middle of
movies. A line connecting all dynamic events was traced to generate kymographs. CCP lifetimes were calculated by measuring
the length of vertical traces on kymographs.
Wound healing assay
30000 cells were seeded in 8-16 replicates in ImageLock 96 well plates (Essen Biosciences). On the next day, cultures were
scratched using a WoundMaker (Essen Biosciences) and imaged for 48 hours on an Incucyte (Essen Biosciences). Migration was
analyzed using the Incucyte software and migration was measured as relative wound density.
Transferrin uptake
50000 cells/well were seeded in at least two 24 well plates (1 plate to measure uptake and the other to measure surface receptor). On
the next day, cells were incubated at 37C for 8 min with pre-warmed serum-free media containing 10 mg/ml Alexa Fluor-488-labeled
human transferrin. After incubation, cells were washedwith PBS, detached with 0.25% trypsin at 37C, received ice-cold serum con-
taining media, spun, washed with ice-cold PBS, fixed with 4% PFA for 10 min at 4C, spun and resuspended in PBS. To measure
surface transferrin receptor, cells were detached using Accutase (Sigma, A6964), washed with ice-cold PBS, incubated on ice for
45 min with serum-free media containing 10 mg/ml Alexa Fluor-488-labeled human transferrin, spun, washed twice with ice-cold
PBS, fixed with 4% PFA for 10 min at 4C, spun and resuspended in PBS. Cells were analyzed using a Sony iCyt Eclipse flow cy-
tometer (Sony Biotechnology Inc) or in a LSRFortessa (BD bioscencies). At least 5000 cells for each replicate were measured for
each experiment. Normalized transferrin uptake was calculated by diving themedian fluorescence signal of the uptakemeasurement
by themedian fluorescence signal of the surface receptor measurement. To combine experiments from different days, the results are
displayed as relative to the average uptake value of the controls for each experiment. Transferrin uptake and surface transferrin re-
ceptor measurements were always performed and measured in parallel. For the dominant negative experiments using ITSN1-SH3d
(Figure 3H), we measured the fluorescence values for transferrin only for cells with high expression levels of the RFP-tagged con-
structs (Cells with RFP signal at least 100 times above background). The values for the uptake and surface transferrin were then
treated and displayed the same way as described above.
Antibody feeding assay
Cells were incubated at 4C for 40 min with serum-free media with an anti-active integrinß1 antibody (12G10) in PBS (1:100 dilution).
After incubation, unbound antibody was removed with two PBS washes. Cells were released from endocytic block by adding pre-
warmed media and incubation at 37C for the indicated periods of time. At the end of the incubation period, surface antibody was
removed by two 2 min washes with stripping buffer (0.5% acetic acid, 0.5 M NaCl) followed by one PBS wash and fixation (4% PFA,
10 min at 4C). Cells were then blocked and permeabilised (PBS, 5% goat serum, 0.5% Triton X-100) followed by incubation with a
Alexa Fluor-488-labeled secondary antibody and imaged. Uptake index was calculated by dividing the background-subtracted
signal by cell area.e5 Cell 174, 325–337.e1–e7, July 12, 2018
Electron microscopy
Cells were grown on MatTek glass-bottomed Petri dishes and fixed in 2.5% glutaraldehyde 2% paraformaldehyde in 0.1 M cacody-
late buffer pH7.4 O/N at 4C. Washed in buffer and postfixed in 1% osmium tetroxide for 1 h at 4C. Dehydrated in an ascending
ethanol series and embedded in CY212 resin. Ultrathin sections were stained with saturated aqueous uranyl acetate and Reynolds
lead citrate and examined using a Tecnai Spirit EM (FEI) operated at 80 KV.
GST pull downs
GST-tagged constructs were expressed in Rosetta (DE3) Escherichia coli overnight at 18C. Cells were harvested, resuspended in
lysis buffer (20 mM Tris pH 8.5, 500 mM NaCl, 2 mM EDTA), lysed using a Constant Cell Disruptor System (Constant Systems) and
spun at 35000 rpm for 20 min at 4C in a Beckman Ti45 rotor. The cleared supernatant was bound to glutathione beads for 1 h at 4C.
Beads were washed extensively with lysis buffer and resuspended in HEPES buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 1 mM
TCEP). Proteins bound to glutathione beads were used directly for pull downs. Rat brain lysates were incubated with protein-bound
beads for 1h at 4C followed by 6 washes with lysis buffer. Recombinant proteins were incubated with protein-bound beads for
10 min at room temperature and also washed 6 times with lysis buffer. Samples were run on SDS-PAGE gels and either immunoblot-
ted or Coomassie stained. Rat brain lysates were prepared as follows: One brain was defrosted on ice and homogenized in a 15 mL
Teflon-glass homogenizer with 4 mL of homogenization buffer (150 mM NaCl, 20 mM HEPES pH 7.5, 2 mM DTT, 1/1000 protease
inhibitor cocktail and 0.1% Triton X-100). The lysate was cleared by centrifugation at 50000 rpm in a Beckman TLA 100.4 rotor.
Protein purification
FCHSD2 proteins used for crystallography, CryoEM, lipid binding and actin polymerization experiments were all expressed from con-
structs with an N-terminal His-SUMO tag. Proteins were expressed in Rosetta (DE3) Escherichia coli overnight at 18C. Cells were
harvested, resuspended in lysis buffer (20 mM Tris pH 8.5, 500 mM NaCl, 20 mM Imidazole), lysed using a probe sonicator and spun
at 35000 rpm for 20 min at 4C in a Beckman Ti45 rotor. The cleared supernatant was passed in a HisTrap FF column (GE healthcare)
and extensively washed with lysis buffer. Bound protein was eluted with elution buffer (20 mM Tris pH8.5, 100 mM NaCl, 200 mM
Imidazole) directly into an anion exchange column (HiTrap Q - GE healthcare). A Tris buffered salt gradient (100 mM to 500 mM
NaCl) was used for elution and fractions containing the protein of interest were incubated overnight at 4C with Sumo protease to
cleave the His-SUMO tag. Proteins were further purified using a Superdex 200 (GE healthcare) size exclusion column using gel filtra-
tion buffer (150 mM NaCl, 20 mM HEPES pH 7.5, 500 mM TCEP). SNX9, CIP4 and cdc42 were purified using the same protocol, with
the exception of the anion exchange step. FCHSD2 BAR-sfGFP used for NTA was purified using the protocol above with the excep-
tion of the anion exchange and the tag removal steps. N-WASP was purified as an N-terminal 6xHis tagged protein from insect cells
(SF9) using the same protocol as described above for E. coli proteins with the exception of the step used to cleave the tag.
Liposome preparation
Liposomes were made by pore extrusion. Lipid mixtures dissolved in methanol were dried in glass tubes by Argon gas, rehydrated
into buffer (20 mM HEPES pH 7.5, 150 mM NaCl) and filtered 20x through 0.8 mm diameter polycarbonate membranes (Nucleopore).
Folch lipids used were a mixture of 1:1 between Sigma (B1502) and Avanti (131101P) brain extract lipids. Defined lipid mixtures were
based on a mixture of 55:20:10, PC:PE:Cholesterol (molar ratio) supplemented with PS or Phosphatidylinositols at 10 or 5 parts,
respectively.
Liposome binding assay
Purified protein (1 mM) was incubated with 125 mg/ml of liposomes for 15min at room temperature and then spun down in a benchtop
ultracentrifuge (Optima TL Ultracentrifuge) for 15 min at 80000rpm (TLA 100 rotor). Resuspended pellets and supernatants were
analyzed by SDS-PAGE.
Actin polymerization assay
Actin was purified from muscle acetone powder as described previously (Doolittle et al., 2013). Pyrene-labeled actin (AP05) and
ARP2/3 complex (RP01P) were purchased from Cytoskeleton Inc. Actin polymerization assays were performed in 40 ml reactions us-
ing 96 well half-area plates. Reactions were started by adding actin to a mix of all other components and actin polymerization buffer
(10x buffer: 500mMKCl, 20mMMgCl2, 10mMATP). Fluorescencewasmeasured in a Tecan Safire2 fluorescence plate reader using
excitation/emission wavelength 365 nm (±20 nm) / 407 nm (±12 nm). All actin polymerization reactions were performed using 3 mM
actin, 25 nM ARP2/3 and 50 nM N-WASP. Liposomes were used at 12.5 mM. To load cdc42 with GTPgS, purified cdc42 was incu-
bated with 1.25 mM EDTA and 4 mM GTPgS for 45 min on ice. GTPgS was then locked in place by adding 4 mM extra MgCl2.
SEC- MALS
Size exclusion chromatography –multi angular light scattering (SEC-MALS)was performed using aWyatt Heleos II 18 angle light scat-
tering instrument coupled to aWyatt Optilab rEX online refractive index detector. Detector 12was replacedwithWyatt’s QELS detec-
tor. Samples for analysis were resolved on a Superdex S-200 10/300 analytical gel filtration column (GE Healthcare) running at
0.5 ml/min in gel filtration buffer (150 mM NaCl, 20 mM HEPES pH 7.5, 500 mM TCEP) before passing through the light scatteringCell 174, 325–337.e1–e7, July 12, 2018 e6
and refractive index detectors in a standard SEC-MALS format. Protein concentration was determined from the excess differential
refractive index based on 0.186 DRI for 1 mg/ml. The concentration and the observed scattered intensity were used to calculate
the absolute molecular mass from the intercept of the Debye plot using Zimm’s model as implemented in Wyatt’s ASTRA software.
Nanoparticle Tracking Analysis
Nanoparticle Tracking Analysis (NTA) was performed as described in (A.C., L.A.-S., and H.T.M., unpublished data). Measurements
were taken on a Nanosight LM10 (Malvern) equipped with a 488nm laser, a 500nm long pass filter, a CMOS camera and a syringe
pump. 800nmextruded liposomes (38:25:20:15:2, DOPC:PE:PS:Cholesterol:PI(3,4)P2molar ratios) were diluted to a concentration of
2-8 x108 particles/ml (1 mg/ml lipids) and FCHSD2-BAR-sfGFP was used at 1nM. 120 s movies at 25 frames per second were re-
corded under flow from the syringe pump (flow setting 50) to reduce bleaching and the tracking and analysis was performed using the
Nanosight NTA software version 3.1 (Malvern). The size distribution of the total liposome population was obtained from movies
measuring total diffracted light while the size distribution of FCHSD2-BAR-sfGFP was obtained from movies measuring only the
emitted light from excited sfGFP detected with the 500 nm long pass filter.
CCV purification
Clathrin-coated vesicles (CCVs) were purified fromHEK 293T cells following the protocol described in Girard et al. (2005). A simplified
protocol flow chart is shown in Figure S6A. Briefly, cells were harvested from 5 confluent 15 cm dishes in buffer A (100 mMMES pH
6.5, 1 mM EGTA, 0.5 M MgCl2) and lysed by 20 strokes with a glass-teflon homogenizer. After centrifugation at 17000x g for 20 min,
soluble proteins and vesicles (S1) were recovered and centrifuged at 56000xg for 1h to separate a crude microsomal fraction from
soluble proteins (S2). Themicrosome pellet was resuspended in buffer A, layered in a Sucrose (8%w/v) Deuterium oxide cushion and
centrifuged at 116000x g for 2 h to obtain a pellet of purified CCVs.
Crystallography
For crystallization, FCHSD2 SH3-2 and ITSN1 SH3d proteins were mixed in a 1:1 molar ratio at a final concentration of 38mg/ml.
Crystallization trials were performed by sitting drop vapor diffusion in 200 nl drops (100 nl protein + 100 nl mother liquor) at 18C.
Crystals used for data collection grew in 0.5 M ammonium sulfate, 10% Glycerol, Tris pH 8.5. Crystals were cryoprotected in
25% glycerol. Data was collected at the Diamond Light Source (line i04-1) at a wavelength of 0.9282 Å. Datasets were integrated
using MOSFLM (Battye et al., 2011) and scaled using SCALA (Evans, 2006). Structure was solved by molecular replacement with
PHASER-MR (McCoy, 2007) using the NMR structures of FCHSD2 SH3-2 (PDB: 2DL7) and ITSN1-SH3d (PDB: 1UE9) as search
models. The structure was solved in the space group I213 with 8 chains (4 dimers) in the asymmetric unit. The structure was refined
by iterative cycles of manual model building in Coot (Emsley et al., 2010) and refinement with Refmac (Murshudov et al., 2011). The
statistics for data processing and refinement are shown in Table S1. Molecular graphics were produced in CCP4MG (McNicholas
et al., 2011).
Single particle CryoEM
For cryo-EM analysis, 3 mL of the sample (F2B1) at 0.15 mg/ml to 0.3 mg/ml were applied to Quantifoil R 1.2/1.3 Au 300 mesh grids,
blotted for 3 – 3.5 s and vitrified in liquid ethane in an FEI Vitrobot MKIII, at 100% humidity at 4C. Data were collected with a Titan
Krios electron microscope (FEI) operated at 300 kV equipped with a K2 Summit direct electron detector (Gatan) mounted after a Ga-
tan Imaging Filter (GIF) with a 20-eV slit. 20-frame image stackswere collected in electron-countingmodewith a flux of 2 e-/Å2/s and a
total dose of 40 e-/Å2 and a calibrated pixel size of 1.1 Å. Frames were aligned and averaged with MOTIONCORR (Li et al., 2013).
Contrast-transfer-function parameters were calculated with Gctf (Zhang, 2016). All subsequent particle picking and data processing
was done in a pre-release of Relion 2.0 (Scheres, 2012). From 766micrographs, Relion autopick selected 230954 particles using as a
reference 2D averages derived from a manually picked particle set. Autopicked particles were used for reference free 2D classifica-
tion. The best 2D classes, containing 30270 particles, were selected for further processing. 3D classification generated classes that
looked very similar to each other. Therefore, we used all particles from the best 2D classes for 3D refinement using a 40 Å low-pass
filtered FES F-BAR structure (pdb 4DYL) as an initial model and applying C2 symmetry. Molecular graphics were produced in
Chimera (Pettersen et al., 2004).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed with Prism 6.0. Student’s t test was used for pairwise comparisons. Tukey’s multiple comparisons
test was used to determine significant differences between multiple samples. Data are presented as mean ± SD or SEM as indicated
in the figure legends. Significance levels used were as follows: *p < 0.05, **p < 0.01, ***p < 0.001.
DATA AND SOFTWARE AVAILABILITY
The accession number for the FCHSD2 SH3-2/ITSN1 SH3d crystal structure reported in this paper is PDB: 6GBU. The accession
number for the cryo-EM map for the FCHSD2 F-BAR reported in this paper is EMDB: EMD-4371.e7 Cell 174, 325–337.e1–e7, July 12, 2018
Supplemental Figures
Figure S1. FCHSD2 Is a Bona Fide CME Protein, Related to Figure 1
(A) Graphs for the recruitment dynamics of FCHSD2 versus ClathrinLC, Dynamin1, ITSN1L and ARP3. Number of events measured are shown at the top left of
each graph. Data are presented as mean ± SD.
(B) Immunoblots for FCHSD2 showing both FCHSD2 CRISPR/Cas9 knockout clones used and the rescue cell line (FCHSD2 KO-1 stably expressing untagged
FCHSD2).
(C) Increased surface and total transferrin receptor (TFR) in FCHSD2 knockout cells shown by immunofluorescence (left), immunoblots (center) and flow cy-
tometry (right). Each value represents median fluorescence from at least 5000 cells (n = 3, mean ± SD). **p > 0.01, *p > 0.05. One-way ANOVA with Tukey’s post
hoc analysis.
(D) Immunoblots showing FCHSD2 knockdown in BSC1 AP2s2-GFP cells.
(E) Immunoblots showing ARP3 knockdown in wild-type and FCHSD2 KO cells.
(F) Immunoblots showing ARP3 knockdown in BSC1 AP2s2-GFP cells.
Figure S2. FCHSD2 Depletion Reduces Integrin Uptake and Affects Cell Migration, Related to Figure 1
(A) FCHSD2 localizes to disassembling focal adhesions. Left: Overview of cell expressing FCHSD2-Venus, mCherry-ClathrinLC and Integrin b3-BFP. Center:
Image series of region marked in (left). The accumulation of FCHSD2 and clathrin occurs only at disassembling focal adhesions. Right: Kymograph showing
FCHSD2 and clathrin advancing in a disassembling focal adhesion. Image series generated at 0.5 frame/minute.
(B) FCHSD2 depletion reduces integrin b1 uptake. Top left: pictorial explanation of the experimental design used for the antibody (Ab)-feeding assay. Bottom left:
representative images of the antibody feeding assay results. Cell boundaries are shown in yellow and internalised antibody signal is shown in white. Right:
quantification of the antibody feeding assay using an antibody recognizing an active form of Integrin b1 (12G10). n = 27, 56, 53 (control); 27, 59, 80 (shRNA); 16, 61,
60 (FCHSD2 KO-1); 43, 51, 71 (FCHSD2 KO-2), mean ± SD. ***p > 0.001, **p > 0.01. One-way ANOVA with Tukey’s post hoc analysis.
(C) Integrin b1 uptake experiment performed by flow cytometry. For this experiment we used labeled Integrin b1 (12G120) antibody (Alexa 488). Each value
represents median fluorescence from at least 5000 cells (n = 4, mean ± SD). ***p > 0.001, **p > 0.01, *p > 0.05. One-way ANOVA with Tukey’s post hoc analysis.
(D) Wound healing migration assay. Left: Representative images of control and knockout cells at time zero and at 24hs after wounding. Cell area is masked in
yellow. Right: quantification of wound area closure over time (mean ± SD).
Figure S3. FCHSD2 Is Not Directly Recruited to CCPs by PI3KC2a or Its Kinase Activity, Related to Figure 2
(A) Top: Transferrin uptake assay by flow cytometry comparing wild-type and FCHSD2 KO cells silenced for PI3KC2a. Uptake of Alexa488 labeled transferrin
normalized by the amount of surface transferrin receptor for each condition and against uptake for the wild-type cells in each experiment. Each value represents
median fluorescence from at least 5000 cells (n = 12, mean ± SD). ***p > 0.001, ns = non-significant. One-way ANOVA with Tukey’s post hoc analysis. Bottom:
Immunoblots showing PI3KC2a knockdown in wild-type and FCHSD2 KO cells.
(B) Kymographs of HeLa FCHSD2-Venus stables silenced for PI3KC2a and control cells. Cells were transfected with mCherry-ClathrinLC 24 hs before imaging.
Kymographs generated from 120 s movies at 1Hz. Note the elongated CCP lifetimes in PI3KC2a knockdown cells as described in Posor et al. (2013).
(C) Autoinhibition of FCHSD2. Representative images of a center slice from cells expressing different FCHSD2 truncation constructs and co-stained with
phalloidin (Actin). The bar graph (upper right) shows the quantification of cellular protrusions/mm for each construct. The non-inhibited BAR domain produces
many protrusions. Numbers inside bars represent number of cells measured. The line graph (bottom right) shows the fluorescence profile of sum intensity
projections for cells expressing each construct. Due to the natural thinning of cells from their centers to the edge, a gradually decaying line indicates that
the fluorescent protein is primarily cytosolic while a flat line with an abrupt fall on the cell edge indicates that the fluorescent protein is primarily bound to the
membrane.While the presence of SH3-1 significantly reduces the generation of cellular protrusions generated by the FCHSD2 F-BAR, a significant fraction of the
protein remains bound to the membrane (green line). Only the combined presence of SH3-1 and SH3-2 is capable to avoid promiscuous binding of the BAR
domain to the membrane. Data is shown as mean ± SD in bar graph and as ± SEM in fluorescence profiles. ***p > 0.001, ns = non-significant. One-way ANOVA
with Tukey’s post hoc analysis.
(D) Immunoblots for intersectin knockdown in FCHSD2-Venus HeLa cells.
Figure S4. FCHSD2 Binds to Intersectin via an SH3-SH3 Interaction, Related to Figure 3
(A) Binding affinity for the FCHSD2 SH3-2 / ITSN1 SH3d interaction measured by isothermal titration calorimetry (ITC).
(B) To highlight the canonical proline-binding interface of FCHSD2 SH3-2, it was aligned with 17 available structures of SH3 domains and their peptides
(Structures used: 1N5z, 1sem, 1cka, 1abo, 1bbz, 1n5z, 1uj0, 1w70, 1ywo, 2df6, 2d1x, 2j71, 2o9v, 2vkn, 2v1r, 3u23, 4f14). Left: The structural alignment reveals the
interface where proline-rich peptides (shown as ribbons) bind on FCHSD2 SH3-2 (shown as surface). Right: The ITSN1 SH3d (also shown as surface) binds to the
canonical proline-binding interface of FCHSD2.
(C) The ITSN1 SH3d was aligned to the same 17 structures as above. The structural alignment reveals that the interaction to FCHSD2 SH3-2 does not involve the
proline-binding interface of ITSN1 SH3d.
(D) Structural localization of residues used as negative control mutants. Localization of residues D538 and N613 in FCHSD2SH3-1 (left) and T1086 in ITSN1 SH3d
(right) forming homotypical crystal contacts. One of the chains is represented as surface to facilitate visualization.
(E) TIRF images of HeLa cells transfected with mCherry-ClathrinLC plus wild-type or interface mutant of GFP-FCHSD2 SH3-2 (Y576S+F607S). The interface
mutant does colocalize with clathrin punctae.
(F) TIRF images of FCHSD2-Venus stable cells transfected with wild-type or interface mutant GFP-ITSN1 SH3d (R1119E). The wild-type construct act as
dominant negative and displaces FCHSD2 from membrane punctae while the interface mutant does not.
(G) Images of endogenous FCHSD2 staining in HeLa cells transfected with mitochondrially targeted wild-type or interface mutant of ITSN1 SH3d (R1119E).
Scale bars = 10mm in overviews, 5mm in insets.
Figure S5. FCHSD2 Activates Actin Polymerization at CCPs, Related to Figure 4
(A) Comparison between polymerization reactions with actin alone and the minimal components Actin, ARP2/3 and N-WASP.
(B) Full experiment as shown in Figure 4B including additional controls.
(C) FCHSD2 strongly activates actin polymerization in the presence of liposomes. Left: Actin polymerization experiments using different FCHSD2 (F2B12
fragment) concentrations. Right: fitting of actin polymerization slopes versus F2B12 concentration. Vertical dashed line shows the half-maximum activity (6.3nM)
(n = 3 experiments, mean ± SD).
(legend continued on next page)
(D) The SH3-1 domain of FCHSD2 does not activate actin polymerization alone. Actin polymerization experiments using FCHSD2 SH3-1 at 500nM and 1mM in the
absence (left) or presence of liposomes (right). The F2B12 fragment was used as a control.
(E) SEC-MALS for FCHSD2 (F2B12 construct). Elution profiles and molecular weight determination for two concentrations of protein as indicated. Horizontal
dotted lines indicate the predicted monomeric (71KDa) and dimeric (142KDa) masses of F2B12. Note that indicated protein concentrations refer to injected
proteins. At elution volume, a 10-fold dilution is expected.
(F) Full experiment as shown in Figure 4C including additional controls.
(G) Actin polymerization experiment showing that CIP4 cannot activate actin polymerization without cdc42.
(H) Effect of FCHSD2 knockout on ARP3 recruitment to CCPs. Images are time projections (20 s) of GFP-Dynamin andmCherry-ARP3. Right: Quantification of the
percentage of Dynamin punctae colocalizing with ARP3 in control and FCHSD2 KO cells. (n = 15, 20, 18 cells for control, FCHSD2 KO(1) and FCHSD2 KO(2)
respectively). Scale bars = 10mm in overviews, 5mm in insets. Data is displayed as mean ± SD. ***p > 0.001, One-way ANOVA with Tukey’s post hoc analysis.
Figure S6. The FCHSD2 F-BAR Is Flat, Related to Figure 5
(A) Left: SimplifiedCCV purification protocol. Fractions in redwere used for western blot. Right: western blot fromCCV purification. 20mg of each fraction per lane.
Note the enrichment of typical CCV markers (Clathrin and AP2 beta) in purified vesicles and the deenrichment for FCHSD2, tubulin and ARP3.
(B) Super resolution Structured Illumination Microscopy (SIM) of overexpressed GFP tagged FCHSD2 F-BAR showing plasma membrane coating and the for-
mation of cellular protrusions. Scale bars = 10mm in overview, 5mm in inset.
(C) Representative electron micrograph and three examples of F2B1 particles on the right.
(D) Selected 2D averages used for 3D reconstruction.
(E) Estimation of the average resolution of the cryo-EM 3D reconstruction on the basis of the gold standard FSC criteria of 0.143.
(F) Comparison between our F2B1 3Dmodel (left) and the Fes F-BAR structure (PDB: 4DYL). Arrows point to similar features between the FCHSD2 F-BAR and the
FES F-BAR.
